ACGLO vs FHN

ACGLO's Piotroski F-Score of 4/9 indicates a borderline stable financial health, falling short of strong resilience. The absence of an Altman Z-Score raises concern about default risk, though the low Debt/Equity (0.12) and strong profitability margins suggest solid balance sheet fundamentals. The stock trades at a deeply undervalued P/E of 4.31 and Price/Book of 0.31, well below sector averages, with a Graham Number of $83.06 and intrinsic value of $138.38, implying significant upside potential. However, the bearish insider sentiment, lack of analyst coverage, and recent price decline undermine near-term momentum despite strong earnings growth.

FHN presents a stark contrast between attractive valuation and deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the current price of $24.21 is a discount to both the Graham Number ($28.16) and the growth-based Intrinsic Value ($58.7), the low health score and bearish insider activity suggest significant underlying risks. These concerns are partially offset by strong earnings growth (29.3% YoY) and a consistent track record of beating analyst estimates. Consequently, the stock is a high-risk value play where growth metrics clash with poor deterministic health indicators.